The recently released report by the UN High Level Panel on Access to Medicines provides several recommendations for making publicly-funded research more widely available, calling for universities and research institutions that receive public funding to prioritise public health objectives over financial returns in their patenting and licensing practices. This, of course, is particularly interesting against the backdrop of South Africa’s legislative mandate to commercialise the output of publicly-financed research and development activities, as stipulated in the country’s legislation.
Report of the United Nations High-Level Panel on Access to Medicines
